胡寓旻 - 中山大学 - 肿瘤防治中心

个人简介

2002年毕业于广州医学院临床医学系。2008 年获得美国德克萨斯大学生物医学研究生院，MD Anderson 癌症中心，生物医学和肿瘤学博士。2010年完成美国MD Anderson癌症中心血液科博士后研究工作，同年入选中山大学“百人计划”引进人才。在美国排名第一的MD Anderson癌症研究中心工作期间，连续获得Rosalie B. Hite Fellowship for Cancer Research、The Kimberly Patterson Fellowship Award for Leukemia Research等多项研究奖项。

研究领域

肿瘤代谢生物学和抗癌新药研发，专长肿瘤细胞的线粒体功能失调、能量以及物质代谢异常、氧化还原/活性氧在消化道肿瘤、肺癌、血液肿瘤等领域的研究以及研发相应的抗癌新药。目前专注于癌基因对肿瘤细胞能量以及物质代谢调控机制研究，期望基于肿瘤细胞与正常细胞在代谢过程的显著差异，寻找对肿瘤细胞有选择性杀伤作用而被正常细胞耐受的治疗新策略，从而攻克现有化疗药物对正常细胞毒性以及靶向药物治疗局限性、耐药性的难题。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Lu W, Hu Y (co-first-author), Chen G, Pelicano H, Chen Z, Zhang H, Huang P et al. “Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy” (2012) Accepted for publication on PLoS Biology 　　2. Hu Y, Lu W, Chen G, Garcia-Manero G, and Huang P. K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Research 2012 Feb;22(2):399-412 　　3. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G, “Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate” Blood (2010) 14;116(15):2732-41 　　4. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P, “Mitochondrial MnSOD Expression in Ovarian Cancer: Role in Cell Proliferation and Response to Oxidative Stress” The Journal of Biological Chemistry (2005) 280(47): 39485-92. 　　5. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, ZengZ, Yang J, Yun J, Xu R and Huang P. Over-Expression of GAPDH in Human Colorectal Carcinoma as a Preferred Target of 3-BrOP. Journal of Bioenergetics and Biomembranes 2012 Feb;44(1):117-25 　　6. Li M, Luo B, Liu Q, Hu Y, Ganesan A, Huang P, Wen S. Synthesis of N-acyl-N,O-acetals Mediated by Titanium Ethoxide. Org. Lett. 2014, 16, 10-13. 　　7. Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, Huang P. Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate. Int J Oncol. 2013 Nov;43(5):1710-8. 　　8. Liu PP, Liao J, Tang J, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH, Huang P. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death & Differentiation, 2013 Oct 4 [Epub ahead of print]. 　　9. Wang P, Mai C, Wei YL, Zhao JJ, Hu Y, Zeng ZL, Yang J, Lu WH, Xu RH, Huang P. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med Oncol. 2013 Jun;30(2):552. 　　10. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, and Hagop M Kantarjian. A phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Accepted for publication on Journal of Clinical Oncology (2012) 　　11. Chen G, Chen Z, Hu Y, and Huang P. Inhibition of Mitochondrial Respiration and Rapid Depletion of Mitochondrial Glutathione by β-Phenethyl Isothiocyanate: Mechanisms for Anti-Leukemia Activity. Antioxid Redox Signal (2011) 15(12):2911-21 　　12. Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, et al. Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leuk Res (2011) 35,351-357 　　13. Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM., and Garcia-Manero G. Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol (2011)86, 237-238. 　　14. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Tambaro FP, Viallet J, O''Brien S, and Garcia-Manero, G. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010)16, 3923-3932. 　　15. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, Yang H, Hu Y, Viallet J, O''Brien S, and Garcia-Manero G. The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy (2010)6, 976-978. 　　16. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, Huang P, “Mitochondrial dysfunction and ROS imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism” Cancer Research (2009) 15;69(6):2375-83. 　　17. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P, “Novel Action of Paclitaxel against Cancer Cells: Bystander Effect Mediated by Reactive Oxygen Species” Cancer Research (2007) 67(8): 3512-3517